Consistent with these results, 24 of the 35 neonates in our study who had CIAD and TBX19 mutations had manifestations of hypoglycemia, jaundice, convulsions, feeding difficulties, and growth retardation (mostly during the neonatal period), 2 cases had recurrent upper respiratory tract infection, and 1 case had sepsis (13, 17, 18). Here, TBX19 is linked to Recurrent upper respiratory tract infections.